| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
IDO-IN-12 targets indoleamine 2,3-dioxygenase (IDO), a heme-containing enzyme that catalyzes the oxidative cleavage of the pyrrole ring of tryptophan to N-formylkynurenine. IDO is a key immunoregulatory enzyme that mediates tryptophan depletion and the accumulation of immunosuppressive kynurenine metabolites in the tumor microenvironment. By inhibiting IDO, IDO-IN-12 blocks this immunosuppressive pathway, potentially enhancing antitumor immune responses. The compound is a research tool for studying the role of IDO in cancer immunotherapy.
|
|---|---|
| ln Vitro |
In vitro, IDO-IN-12 inhibits indoleamine 2,3-dioxygenase (IDO) enzyme activity. The compound blocks the rate-limiting step of tryptophan catabolism, reducing the production of immunosuppressive kynurenine metabolites. IDO-IN-12's in vitro activity has been characterized in enzymatic assays using purified recombinant IDO or in cell-based assays using IDO-expressing cells. The compound is used as a research tool to study the role of IDO in immune suppression. Detailed IC50 values are not specified in publicly available literature.
|
| ln Vivo |
Detailed in vivo activity data for IDO-IN-12 are not extensively documented in publicly available literature. As an IDO inhibitor, IDO-IN-12 is expected to enhance antitumor immune responses by relieving IDO-mediated immunosuppression in the tumor microenvironment. The compound is being investigated for its potential applications in cancer immunotherapy. Further in vivo studies are needed to fully characterize its therapeutic potential in animal models of cancer. IDO-IN-12 is extracted from patent WO 2017181849 A1.
|
| Enzyme Assay |
Enzyme activity assays for IDO-IN-12 are performed using purified recombinant IDO enzyme. IDO activity is measured by monitoring the conversion of tryptophan to N-formylkynurenine. IDO-IN-12 is incubated with the enzyme and substrate (L-tryptophan) at varying concentrations in appropriate assay buffer. The reaction is stopped, and product formation is quantified by measuring absorbance at 321 nm or by HPLC. IC50 values are calculated from concentration-response curves. Nonspecific activity is determined in control reactions without inhibitor.
|
| Cell Assay |
Cellular assays for IDO-IN-12 are performed using cell lines that express IDO, such as cancer cell lines or immune cells treated with IFN-gamma to induce IDO expression. Cells are cultured in appropriate media and treated with IDO-IN-12 at varying concentrations for defined time periods. IDO activity is assessed by measuring the levels of tryptophan and kynurenine in the culture supernatant using HPLC or LC-MS/MS. Cell viability is assessed using standard assays such as MTT or CellTiter-Glo. The compound's effects on T cell proliferation may be assessed in co-culture assays.
|
| Animal Protocol |
In vivo studies with IDO-IN-12 are conducted in mouse tumor models to evaluate the compound's ability to enhance antitumor immune responses. IDO-IN-12 is administered via appropriate routes (e.g., oral or intraperitoneal) at defined doses and schedules. Tumor growth is monitored by caliper measurements. Immune cell infiltration and activation in the tumor microenvironment are assessed by flow cytometry or immunohistochemistry. Kynurenine levels in plasma and tumor tissues are measured by LC-MS/MS. The compound's immunomodulatory effects are being investigated.
|
| ADME/Pharmacokinetics |
IDO-IN-12 has a molecular weight of 416.23 and a molecular formula of C13H11BrFN5O3S. The compound is extracted from patent WO 2017181849 A1. Detailed pharmacokinetic data for IDO-IN-12 are not extensively documented in publicly available literature. As a small molecule IDO inhibitor, its absorption, distribution, metabolism, and excretion properties are subjects of ongoing research. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for IDO-IN-12 are not extensively documented in publicly available sources. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and adherence to institutional biosafety and chemical hygiene guidelines. The compound has a purity of >99%.
|
| References | |
| Additional Infomation |
IDO-IN-12 is a small-molecule inhibitor of indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes the rate-limiting step of tryptophan catabolism. By blocking IDO activity, IDO-IN-12 reduces the production of immunosuppressive kynurenine metabolites. IDO-IN-12 is extracted from patent WO 2017181849 A1 and is used as a research tool to study the role of IDO in immune suppression and cancer immunotherapy. The compound is for research purposes only.
|
| Molecular Formula |
C13H11BRFN5O3S
|
|---|---|
| Molecular Weight |
416.225543260574
|
| Exact Mass |
414.975
|
| CAS # |
1888341-29-4
|
| PubChem CID |
118973753
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
502
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(=O)N(C2=CC=C(F)C(Br)=C2)C(C2C(NCCSC)=NON=2)=N1
|
| InChi Key |
OOHHWEREOQPCCR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H11BrFN5O3S/c1-24-5-4-16-11-10(17-23-18-11)12-19-22-13(21)20(12)7-2-3-9(15)8(14)6-7/h2-3,6H,4-5H2,1H3,(H,16,18)
|
| Chemical Name |
4-(3-bromo-4-fluorophenyl)-3-[4-(2-methylsulfanylethylamino)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~240.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4025 mL | 12.0126 mL | 24.0252 mL | |
| 5 mM | 0.4805 mL | 2.4025 mL | 4.8050 mL | |
| 10 mM | 0.2403 mL | 1.2013 mL | 2.4025 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
